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revasculadzation) without TLR (targ~t lesion revascularization) was higher in those wlth 
re-treatment eomparad to no re-treatment (19.2% vs. 3.4%, p--0.02). 
Conclusions: Re-treatment after gemme radlation Is performecl in one-third casas, often 
rasulting in additional stent implantation. Re-treatment is associated with increasad TVR 
at follow-up, probebly due to injury outside the irradlated segment. If re-traatment is 
requirnd, vigorous efforts to avoid injury to inadequately irmdiated vassel segments and 
additional stenting should be made. 
No re-treatment Re-treatment p Value 
New stents (%) 12 42 <0.01 
Reference diam (mm) 2.84=0.45 2.86±0.40 0.8 
Lesion length (mm) 18.1 ±8.6 20.1 ±9.1 0.2 
Pre-MLD (mm) 0.60±0.44 0.58±0.42 0.8 
Final MLD (mm) 2.69±0.53 2.68±0.52 0.9 
In-hosp MACE (%) 0 2.1 0.3 
9-month MACE (%) 13.1 11.1 1.0 
9-month death (%) 2.1 0 1.0 
9-month MI (%) 2.1 8.9 0.08 
9-month TVR (%) 12.1 22.2 0.14 
9-month TLR (%) 10.1 6.7 0.8 
9-month TVR without TLR (%) 3.1 17.8 <0.01 
1196-22 Efficacy of Gamma Vascular Brachytherapy for Ostlal 
Versua Nonostlal In Stent Reatenotlc Leslons 
Costantino O. Costantini. Alexandra J. Lansky, Roxana Mehren, Martin Fahy, Kazuyuki 
Shirai, Nishi Dave, Gregg W. Stone, George Dangas, Martin B. Leon, Cardiovascu/ar 
Rasasrch Foundation, New York Cit~, New York. 
Background: In stent restenosis (ISR) involving the coronary ostium is associated with 
high recurrence rates after conventional treatment compared to non-ostial lesions. 
Whether Gemme vascular bmchytherapy (GVBT) signiflcantly improves these outcomes 
is not known. Methods: Pts with native ostial coronafy lasions (N=45) ware salected from 
a pooled angiographic database of pts enrolled in Vascular Brachytherapy (VBT)tdals for 
treatment of ISR and ware compared to 232 pts with non-ostial lesions, matched for 
lesion length. Baseline and follow-up quantitative coronary angiographic (QCA) analysis 
ware assassad and compared. Results: At basaline pts with ostial lesions had more com- 
plax lesions (ACC/AHA • BI: 73.3% vs. 53.8%, p<0.05), with mora total occlusions 
(8.9% vs. 3.0%, p=0.08) compared to non-ostial pts. QCA results are presented in the 
table. 
Patients with VBT failure had a significant redustion in lesion length regardless the lesion 
Iocation: ostial (14.2±9.49 to 6.94±3.69,p<0.05) and non-ostial (16.66±6.71 to 8.61±6.52, 
p<0.005).There ware no difference in stent eclge restenosis (6.7% vs. 9.1%,p=0.77) Con- 
clusions: Gamma radlation is at least as effective for treatment of ostial in-stent rest- 
enotic lesions as non-ostial lasions, decreasing rastenosis by 54% comparecl to non- 
ostial lesions. The diflerance was not ralated to edge restenosis. 
QCA analysis Ostial Non-Ostial p Value 
Lesion length Pre(mm) 14.2±9.4 16.6±6.7 0.25 
Lesion length FU(mm) 6.9±3.6 8.6±6.5 0.07 
Reference (mm) 2.71±0.39 2.61±0.46 0,15 
Final DS% 26.9±14,5 27.8±12.2 0,67 
FU DS% 36.8±21.7 47.2±25.1 0.009 
Late Loss (mm) 0.31±0.58 0.52±0.70 0.05 
Restenosis (%) 17.8 32.8 0.04 
1196-23 Repeat Intracoronary Radlatlon for In-Stent Restenoala 
in Patlents Who Falled Radlation Therapy: Re-WRIST 
Ron Waksman, Andrew E. Ajani, Edouard Cheneau, Rosanna C. Chen, Bill G. Bass, 
Katayoun Khosravani, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Ellen 
Pinnow, Josaph Lindsay, Washington Hospital Center, Washington, Dist. of Columbia. 
Background: Intracoronary Radiation (IR) is proven as an effective therapy to prevent 
recurrences of in-stent restenosis (ISR). However nearly 20% of the patients (pts) 
enrolled in radiation studies for ISR requiracl repeat revasculadzation to the irradiated 
site. Re-WRIST (Washington Radiation for In-Stent Restenosis Tdal) is a registry evalu- 
ating the safety and efficacy of re-treatment with IR in pts with refractory ISR. 
Methode: Patients with ISR who had recurrence of stenosis at a previously irradiated 
segment and failed a subseguent additional angioplasty were eligible for re-treatment 
with IR, if evaluated as a poor surgical candidate. In Re-WRIST, the radiation system is a 
0.0030-inch nylon ribbon containing 1921r seeds manufacturad by Bast Industries deliv- 
ered into a non-centered end lumen deliver/catheter (Cordis 4F or Mecltronic 5F). The 
prescdbed dose is 15 Gy to a 2 mm radial distence from the center of the souroe. All pts 
receive 6 months of clopidogrel post-procedure. Patients are followed clinically, angio- 
graphically and by IVUS at 6 and 24 months. 
Resulta: At present, 9 pts have been enrolled in the Re-WRIST registry, The mean age 
of the cohort is 65 ± lOyrs (4 males, 3 diabetics and 7 pts had previous CABG). Five ISR 
lesions were in native coronary artedes, 3 in saphenous vein graf'La nd one in left inter- 
nal mammary artery. The mean time interval between radiation treatments is 18 months 
(range 6.4-28.9) and the mean number of previous interventions to the target lesion is 
4.1 ± 1.5. The rediation was delivered successfully in all pts with no procedurel or hospi- 
tal complicattons. Balloon angioplasty alone was performed in 6 of 9 pts, 2 pts ware 
treated with the excimer laser and 1 pt wlth the cutting balloon. None of the pts received 
addiUonal stents. At 30 days, there were no reported clinical events. 
Concluelone: Repeat radlation to the same site using 192-1r for refractory ISR is safe 
and effective at 30 days. Complete 6-month clinical and anglographic follow-up will be 
available at prosentation. 
1196-24 Age la an Important Predi¢tor of Cllnical Out±omas 
Following Intracoronary Radlatlon Therapy for  In.Stent 
Restenoals 
Andrew E. Aiani. Edouard Cheneau, R. Larry White, Bill G. Base, Augusto D. Pichard, 
Lowell F. Satler, Kenneth M. Kent, Melanie Odnger, Chades Duncan, Ellen Pinnow, 
Josaph Lindsay, Ron Waksman, Washington Hospital Center, Washington, Dist. of 
Columbia. 
Beckground: Intracoronary radiatfon therapy (IRT) reduces the recurrence rate of in- 
steht restenosis (ISR) by inhibition of smooth muscle cell prollferatlon. The ability of 
these cells to replicate is limited with age due to changes in the telomeres. The purpoas 
of this study was to assess the effect of age on clinical outcomes following IRT for ISR. 
Methode: We evaluated 1275 paflents (pts) with 6-month (mo) clinlcal follow-up who 
ware enrolled in radiation tdals for ISR using gamma and bete emitters conducted at the 
Washington Hospital Center. Patients with ISR who ware assigned to IRT (N=1025) or 
placebo (N=250) ware analyzed In 4 age groups: (<55 yrs, 55-64 yrs, 65-75 yrs, >75 yrs). 
Reaulta: Baseline clinical and angiographic harectedstics ware similar within each age 
group of IRT pts, except for a higher rate of diabetes in younger pts (42% in pts <75 yrs 
vs. 30% in pts >75 yrs, p=0.002) and a higher rate of previous CABG in older pts (58% in 
pts >75 yrs vs. 37% in pts <55 yrs, p< 0.001). The clinical outcomes at 6 mos for IRT 
troated pts ere shown (Table). No effect of age was sasn in placebo pts. IRT trasted pts 
had reduced MACE compared to placebo in all age groups, driven by reduced terget ves- 
sal rovascularization (TVR). Multivadate analysis detected age as an independent pro- 
dieter of MACE at 6 mths (odds ratio 0.8, CI. 0.70-0.93, p=0.O04). Concluelona: Elderly 
pts (>75 yrs) potentially derive the maximum benefit from IRT for ISR as recurrent rest- 
enosis is sIgnificantly recluced compared to younger pts. 
• 55 yrs 55-64 yrs 65-75 yrs >75 yrs P 
(N=268) (N=.321) (N=314) (N=122) 
Death, % 1 3 4 4 NS 
Q-Wave-MI, % 2 1 1 1 NS 
TLR, % 19 21 13 8 0.002 
TVR, % 28 26 19 16 0.005 
MACE, % 28 28 20 18 0.02 
Late Thrombosis, % 3 2 1 1 NS 
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1197-6 Neuroprotect ion Redu¢es the Risk of PerI-Procedural 
Major Strokea and Death in Octogenarlana 
Chdstina Brennen, Gary S. Roubin, Sriram S. lyer, Sara Mgaieth, Pallavi Kumar, Nadim 
AI-Mubamk, Roxana Mehren, George Dangas, Martin B. Leon, Jiri J. Vitek, Gishel New, 
Lenox Hill Hasrt and Vascular Institute, NY, New York, Cardiovascular Resasrch 
Foundation, NY, New York. 
Ba¢kground: Our previous work in carotid stenting (CS) suggested that patients > 80 
years of age compared with those < 80 am higher- risk for proceclural related stroke. 
Since then, we have altered our strategy of performing CS in » 80 years untier neuropro- 
te±tion (NP). The alm of this study was to compare procedural outcomes in patients _> 80 
years with and wlthout distel embolic protection. 
Methode: Thirty- day outcomes (TIA, minor strokes, major strokes and myocardial inf- 
arction) wem prospectively examined in those patients > 80 years of age who had under- 
gone CS with and without NP. 
Resultl: There ware no differences in age, % female, presence of risk factors, CAD, 
contralateral occlusion, and procedural success between the two groups. There were 
more patients in the NP group who ware asymptomatic (64% vs. 44%), and with prior 
carotid endarterectomy (23% vs. 10%). 
30 Day Out¢omas Wlthout NP Wlth NP 
Patient 91 47 
Minor Stroke 7 (7.7%) 3 (6.4%) 
Major Stroke 6 (6.6%) 0 
Fatal Stroke t (1.1%) 0 
Non- Stroke Death 1 (1.1%) 1 (2.1%) 
Total 15 (16%) 4 (8.5%) 
*P= 0.06 
